Imperial Prostate

16/02/2026

Salvage focal therapy for radiorecurrent prostate cancer has comparable 10-year cancer-specific survival to radical prostatectomy, but fewer complications in matched analyses

Read our latest paper just published in JAMA Oncology by Alexander Light, Max Peters, Taimur Shah, and Hashim Uddin Ahmed! https://lnkd.in/eswimi_W

Plus read the fantastic editorial by John Nikitas and Neha Vapiwala from American Society for Radiation Oncology (ASTRO) putting our work into context: https://lnkd.in/e9WhrteN

With fantastic media coverage from Imperial College London https://lnkd.in/eMm5ChYn and Imperial College Healthcare NHS Trust https://lnkd.in/eu4UZu6S in conjunction with Prost8

And lastly, a huge thank you to our collaborators across the globe who contributed to this work: Manit Arya, Mariana Bertoncelli Tanaka, Mr Tim Dudderidge, Amr Emara, Mark Emberton, Alistair Grey, Richard Hindley, Marc Laniado, Stuart McCraken, Caroline Moore, Raj Nigam, Mohamed Noureldin, Clément ORCZYK, Deepika Reddy, Jaspal Virdi, Mohamed Ahmed, Simone Albisinni, Paul Cathcart, Steven Joniau, Robert Jeffrey Karnes, Raj Persad, Pawel Rajwa, Rafael Sanchez-Salas, Shahrokh Shariat, MD, Joseph A. Smith, Derya Tilki, MD, MBA, Henk van der Poel, Giorgio Calleris, Giancarlo Marra

In localized radiorecurrent , salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.

https://ja.ma/3Oj3srk

04/12/2025

📣 November was a big month for IP7-PACIFIC: we’ve now successfully randomised 1,735 patients!

RCT1️⃣ bpMRI vs mpMRI
RCT2️⃣ image-fusion vs visual estimation targeting

📣 Top sites in Nov/25
•🥇 Northampton – 20
•🥈 St Peter’s – 14
•🥉 Cumberland – 12

Thank you to all of our hard-working sites and especially our funders Cancer Research UK 🙏

30/11/2025

The future of screening starts TODAY 🔬

The first men have now been invited to Prostate Cancer UK's ambitious £42m TRANSFORM trial – the biggest prostate cancer screening study in a generation ▶️ https://www.imperial.nhs.uk/about-us/news/transform-trial-launches-nov-25

Led by researchers at our Trust and Imperial College London, alongside co-investigators at UCL, Queen Mary University of London and the The Institute of Cancer Research, the landmark trial aims to find a way to make diagnosis earlier, safer, and more effective.

Our Trust is the first site to open, with patients from north west London being invited to participate. More sites across the UK will open soon.

Professor Hashim Ahmed, Chief Investigator of the TRANSFORM trial and Chair of Urology at Imperial College Healthcare NHS Trust and Professor of Urology at Imperial College London said: "TRANSFORM is truly game-changing. As the biggest and most ambitious trial I’ve ever been part of, the start of recruitment today marks a pivotal step towards getting the results men urgently need to make prostate cancer diagnosis safe and more effective so that we can unlock the potential of prostate cancer screening in the UK.

“Combining our world-class team of UK researchers, the latest screening techniques like fast MRI scans, PSA blood tests and genetic tests, we can find the best way to screen men for prostate cancer – minimising late diagnosis, saving more lives and doing so with fewer harms. Importantly, we’ve designed the study so that we can evaluate promising new tests as soon as they’re developed."

Imperial Prostate | |

14/10/2025

is a pivotal randomised controlled trial for men with prostate cancer on active surveillance, comparing the UK NICE-guided standard of care VS a regular MRI-based active surveillance pathway

🚀 Our aim: to determine which strategy better detects prostate cancer progression over 5 years

🌟 A tremendous effort from our 🔟 participating sites has been made to already open and recruit over 145 patients from across the country!

Thank you to NIHR (National Institute for Health and Care Research) HTA for funding this and to all our investigators, research teams and participants driving this trial forward!

🏥 Interested in changing practice? New sites welcome — join us!
✉️ atlas@imperial.ac.uk

06/10/2025

TRANSFORM IS COMING!

The TRANSFORM Co-Leads and Trial Management Group met last week for the final face to face meeting before the study kicks off.

TRANSFORM will provide the definitive evidence that the UK National Screening Committee needs before it can make a recommendation on screening for prostate cancer. Organising a national screening trial is a huge undertaking - which is why the study team includes some of the best minds in the country with a wealth of experience.

It is absolutely critical that we get this trial right so we can provide the answers that so many men and their families are looking for.

Thank you to all of our co-investigators for the incredible amount of time and effort you have put in to get us to this point, and especially to our funders Prostate Cancer UK and National Institute for Health and Care Research for supporting this important trial.

03/10/2025

With the prostate cancer screening trial getting started, it is imperative that we can offer a treatment that improves the balance between the harms and benefits of treating localised prostate cancer.

“aims to spare men the incontinence, impotence and even pe**le shortening that have made treating the disease one of the most controversial and polarizing fields in medicine.”

Read the latest interview with Prof Hashim Uddin Ahmed in Bloomberg: https://lnkd.in/eM3feVzH

Imperial College Healthcare NHS Trust Imperial College London

This link will take you to a page that’s not on LinkedIn

29/09/2025

👏 A final robotic prostatectomy for our NIHR Clinical Lecturer Mr Martin J Connor under the mentorship of our senior robotic prostate surgeon Mr Mathias Winkler and assisted by our amazing robotic theatre nursing team at Charing Cross Hospital (Imperial College Healthcare NHS Trust).

Wishing him all the best as he moves clinically to The Royal Marsden Hospital.

29/04/2025

That’s a wrap on for Team IP!

See you in Washington DC for ! 🇺🇸

29/04/2025

Update of presented by Archana Gopalakrishnan at 🇺🇸

This pivotal RCT will evaluate MRI-based surveillance for patients with GG1-2 cancer starting active surveillance

Recruitment is open across the UK!

29/04/2025

Update of presented by Alexander Light at 🇺🇸

This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy

>1200 patients recruited across the UK - watch this space

28/04/2025

In further data, Chase Ng shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without

🇺🇸

28/04/2025

Pilot results from hashtag on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by Hashim Uddin Ahmed

Take home - these treatments are safe and justified

Recruitment for the main trial has completed - PFS endpoint to be reported 2027 🇺🇸